Do you want to read an article? Please log in or register.
Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer
Lung Cancer
Related content
Lung Cancer
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Clin Lung Cancer
Sakata Y, Saito G, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T
doi: 10.1016/j.cllc.2025.05.015
Lung Cancer
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Lancet Respir Med
Shi Y, Wu L, Ji Y, Chen G, Li B, Bi M, Yang R, Miao L, Zhang G, Gao H, Sun L, Zhang M, Cang S, Sun M, Yao W, Pan Z, Cui J, Xiao Y, Wang Q, NCT04143607 Study Group
doi: 10.1016/S2213-2600(25)00121-3
Lung Cancer
Efficacy and Safety of EGFR-TKI Combined With Early Brain Radiotherapy Versus TKI Alone in Patients With EGFR-Mutated NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis
Clin Lung Cancer
Zeng Z, Feng S, Gao T, Chen C, Chen J, Chen J, Lian Y
doi: 10.1016/j.cllc.2025.04.010
RECOMMENDED
Lung Cancer
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME
doi: 10.1016/j.lungcan.2025.108551
Lung Cancer
Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy
Clin Lung Cancer
Fortman D, Wang H, VanderWeele R, Evans T, Herman JG, Rhee J, Reyes V, McLaughlin B, Wozniak A, Somasundaram A, Mekhail T, Socinski MA, Schulze K, Villaruz LC
doi: 10.1016/j.cllc.2024.10.014
RECOMMENDED
Lung Cancer
A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Zerdes I, Kamali C, Johannsdottir B, Blasi M, Assmann C, Kazdal D, Stenzinger A, Skribek M, Ekman S, Christopoulos P, Tsakonas G
doi: 10.1016/j.lungcan.2024.108065
Lung Cancer
In the context of the era of targeted therapy: evaluation of the survival benefits of different local treatment modalities for patients with 1-3 brain metastases from non-small cell lung cancer
Sci Rep
Sun L, Chen H, Yang Z, Li L, Ying Z, Qu Y, Tong N, Sun C, Xia L
doi: 10.1038/s41598-025-10042-w
RECOMMENDED
Lung Cancer
Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Atlagh L, Toublanc AC, Roch B, Marinello A, Ruuth-Praz J, Cousin S, Chouaid C, Basset C, Evrard S, Duruisseaux M, Girard N, Durand K, Mazières J, Brindel A
doi: 10.1016/j.cllc.2025.06.005
Further Publications
EGFR-mutant lung adenocarcinoma transformed into small cell Lung cancer: A case report and literatures review
Respir Med Case Rep
Chen J, Huang H, Zhong P, Peng S, Zhu X, Ding X, Wang F, Kong P, Song T, Lu Z, Chen L
doi: 10.1016/j.rmcr.2025.102219